

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Vitorovic Stefan</u> (Last) (First) (Middle) C/O PRAXIS PRECISION MEDICINES, INC. ONE BROADWAY, 16TH FLOOR (Street) CAMBRIDGE MA 02142 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Praxis Precision Medicines, Inc. [PRAX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 10/20/2020	
	4. If Amendment, Date of Original Filed (Month/Day/Year) 10/20/2020	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/20/2020		C		2,689,329	A	(1)	2,689,329	I	See Footnote ⁽²⁾
Common Stock	10/20/2020		P		250,000	A	\$19	2,939,329	I	See Footnote ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series B Preferred Stock	(1)	10/20/2020		C		4,150,000		(1)	(1)	Common Stock	1,939,295	\$0	0	I	See Footnote ⁽²⁾
Series B-1 Preferred Stock	(1)	10/20/2020		C		551,794		(1)	(1)	Common Stock	257,853	\$0	0	I	See Footnote ⁽²⁾
Series C Preferred Stock	(1)	10/20/2020		C		171,410		(1)	(1)	Common Stock	80,100	\$0	0	I	See Footnote ⁽²⁾
Series C-1 Preferred Stock	(1)	10/20/2020		C		881,835		(1)	(1)	Common Stock	412,081	\$0	0	I	See Footnote ⁽²⁾

Explanation of Responses:

- All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.
- These shares are held directly by Vida Ventures, LLC, a United States limited liability company. The Reporting Person is a managing director of Vida Ventures, LLC and is also a member of the board of directors of the Issuer. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any.

Remarks:

This Form 4/A amends the Form 4 filed on October 20, 2020 to report Vida Ventures, LLC's purchase of 250,000 shares of Common Stock in the Issuer's initial public offering.

/s/ Alex Nemiroff, as Attorney-in-Fact 02/16/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.